SomnoMed posts record Q4 and delivers on FY22 revenue guidance

PLANO, Texas, July 26, 2022 /PRNewswire/ -- SomnoMed Limited (ASX " SOM " , or the Company), a leading company in the provision of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea ( ' OSA ' ), is pleased to provide its quarterly activities report for the period ended 30 June 2022 (Q4 FY22).SomnoMed posts record Q4 and delivers on FY22 revenue guidance.HighlightsRecord quarterly revenue of $21.3 million for Q4 FY22, +32% (+32% in constant currency) versus the previous corresponding period (pcp). On an underlying basis, when excluding the Q4 FY21 COVID-19 related HIC1 allowance, Q4 FY22 revenue was up +36% (+37% in constant currency) versus pcpFull year unaudited revenue of $72.6 million, up +16% (+17% in constant currency) versus pcp and above guidance of +15% growth for FY22. On an underlying basis, when excluding the COVID-19 related HIC1 allowance, FY22 revenue was up +19% (+20% in constant currency) versus pcpFY22 guidance of breakeven EBITDA2 remainsThe record quarter reflects the impact of successful sales and marketing initiatives in all regions, with business conditions improving and the overall trend of patient activity and engagement with their medical clinician normalizing post COVID-19Total patients treated worldwide now exceeds 715,000Development of Rest Assure ®, the Company ' s first ever in-built technology-enabled oral appliance progressed during the quarter, with the secon...
Source: Dental Technology Blog - Category: Dentistry Source Type: news